A little off the main topic here
but this same article also contains the following information:
"Although the study was not designed to look at outcome, the researchers determined that 42 of 48 patients had a clinical response (16 complete responses and 26 partial responses) from the neoadjuvant treatment, and five patients experienced cardiotoxicity."
The chemo used in the study was Navelbine, which was chosen "because we found it has few side effects," according to the researchers.
I point this out only because I believe the cardiotoxicity associated with Herceptin is much higher than we are led to believe, and it is interesting to see that demonstrated here.
Hopeful
|